MediPharm Labs Corp.
MEDIF
$0.04
$0.00-1.65%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.70% | 12.83% | 3.89% | 28.18% | 13.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.70% | 12.83% | 3.89% | 28.18% | 13.29% |
| Cost of Revenue | 33.47% | 23.24% | -9.14% | 76.79% | 55.83% |
| Gross Profit | -20.64% | -6.85% | 34.56% | -18.87% | -27.31% |
| SG&A Expenses | -18.33% | 19.43% | -31.07% | 30.95% | -14.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -17.20% | -334.02% | 16.16% | -324.50% | 605.18% |
| Total Operating Expenses | 8.68% | 20.64% | -19.67% | 53.06% | 16.93% |
| Operating Income | 17.78% | -54.15% | 87.79% | -130.36% | -33.06% |
| Income Before Tax | 23.53% | -44.34% | 89.93% | 45.18% | 37.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.53% | -44.34% | 89.93% | 39.81% | 36.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.53% | -44.34% | 89.93% | 39.81% | 36.96% |
| EBIT | 17.78% | -54.15% | 87.79% | -130.36% | -33.06% |
| EBITDA | 16.87% | -97.04% | 99.17% | -91.68% | -56.99% |
| EPS Basic | 24.49% | -40.43% | 90.91% | 44.44% | 39.51% |
| Normalized Basic EPS | 23.33% | -51.85% | 89.47% | -111.11% | -15.38% |
| EPS Diluted | 24.49% | -40.43% | 90.91% | 44.44% | 39.51% |
| Normalized Diluted EPS | 23.33% | -51.85% | 89.47% | -111.11% | -15.38% |
| Average Basic Shares Outstanding | 2.36% | 2.61% | 2.83% | 9.01% | 3.15% |
| Average Diluted Shares Outstanding | 2.36% | 2.61% | 2.83% | 9.01% | 3.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |